The results of this study support our previous findings, and those of others, that increased bone mass resulting from exogenous MSC cytotherapy [15] or treatment with DKK1-neutralizing antibody [15], Wnt3a [18], or lithium chloride [17] negatively impact MM tumor burden in bone. This evidence concerns the gene WNT3A and neoplasm.